How do we assess a racial disparity in health? Distribution, interaction, and interpretation in epidemiological studies.


Journal

Annals of epidemiology
ISSN: 1873-2585
Titre abrégé: Ann Epidemiol
Pays: United States
ID NLM: 9100013

Informations de publication

Date de publication:
01 2019
Historique:
received: 24 11 2017
revised: 25 07 2018
accepted: 25 09 2018
pubmed: 22 10 2018
medline: 23 10 2019
entrez: 22 10 2018
Statut: ppublish

Résumé

Identifying the exposures or interventions that exacerbate or ameliorate racial health disparities is one of the fundamental goals of social epidemiology. Introducing an interaction term between race and an exposure into a statistical model is commonly used in the epidemiologic literature to assess racial health disparities and the potential viability of a targeted health intervention. However, researchers may attribute too much authority to the interaction term and inadvertently ignore other salient information regarding the health disparity. In this article, we highlight empirical examples from the literature demonstrating limitations of overreliance on interaction terms in health disparities research; we further suggest approaches for moving beyond interaction terms when assessing these disparities. We promote a comprehensive framework of three guiding questions for disparity investigation, suggesting examination of the group-specific differences in (1) outcome prevalence, (2) exposure prevalence, and (3) effect size. Our framework allows for better assessment of meaningful differences in population health and the resulting implications for interventions, demonstrating that interaction terms alone do not provide sufficient means for determining how disparities arise. The widespread adoption of this more comprehensive approach has the potential to dramatically enhance understanding of the patterning of health and disease and the drivers of health disparities.

Identifiants

pubmed: 30342887
pii: S1047-2797(17)31068-2
doi: 10.1016/j.annepidem.2018.09.007
pmc: PMC6628690
mid: NIHMS1509946
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-7

Subventions

Organisme : NIAAA NIH HHS
ID : K01 AA021511
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01 MD011680
Pays : United States
Organisme : NICHD NIH HHS
ID : T32 HD007168
Pays : United States
Organisme : NCI NIH HHS
ID : K01 CA172717
Pays : United States
Organisme : NICHD NIH HHS
ID : P2C HD050924
Pays : United States

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Ann N Y Acad Sci. 2010 Feb;1186:5-23
pubmed: 20201865
Am J Public Health. 2015 Jul;105 Suppl 3:S534-43
pubmed: 25905819
Alcohol Clin Exp Res. 2014 Jun;38(6):1662-70
pubmed: 24730475
MMWR Suppl. 2013 Nov 22;62(3):1-2
pubmed: 24264482
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):83-9
pubmed: 26503034
Am J Epidemiol. 2016 Aug 15;184(4):315-24
pubmed: 27489089
Arch Intern Med. 2006 Dec 11-25;166(22):2437-45
pubmed: 17159008
J Stud Alcohol Drugs. 2016 Mar;77(2):185-98
pubmed: 26997174
Int J Health Serv. 2000;30(1):211-6
pubmed: 10707306
J Epidemiol Community Health. 2003 Jun;57(6):444-52
pubmed: 12775792
Am J Epidemiol. 1980 Oct;112(4):467-70
pubmed: 7424895
BMJ. 2014 Jul 10;349:g4164
pubmed: 25011450
Am J Epidemiol. 2005 Mar 1;161(5):423-33
pubmed: 15718478
Psychol Bull. 2014 Jan;140(1):188-223
pubmed: 23477449
Am J Epidemiol. 2014 Dec 15;180(12):1150-8
pubmed: 25395027
Eur J Epidemiol. 2016 Apr;31(4):337-50
pubmed: 27209009
Int J Health Serv. 2000;30(1):217-9
pubmed: 10707307
Scientifica (Cairo). 2016;2016:8290435
pubmed: 27073716
Am J Epidemiol. 1974 Jun;99(6):385-8
pubmed: 4841816
SSM Popul Health. 2016 Dec;2:123-129
pubmed: 27152319
Annu Rev Public Health. 2016;37:17-32
pubmed: 26653405
Hypertension. 2011 Mar;57(3):383-9
pubmed: 21300667
Atherosclerosis. 2015 Jul;241(1):12-7
pubmed: 25941991
Sci Rep. 2015 Sep 14;5:14005
pubmed: 26364564
Annu Rev Public Health. 2006;27:167-94
pubmed: 16533114
Am J Epidemiol. 2014 Jun 15;179(12):1484-92
pubmed: 24812158
Am J Hypertens. 2013 Nov;26(11):1328-34
pubmed: 23864584
Ann N Y Acad Sci. 2010 Feb;1186:69-101
pubmed: 20201869
Int J Epidemiol. 2012 Apr;41(2):514-20
pubmed: 22253321
Natl Vital Stat Rep. 2017 Apr;66(3):1-64
pubmed: 28437241
Epidemiology. 2014 Jul;25(4):473-84
pubmed: 24887159
JAMA Intern Med. 2016 Sep 1;176(9):1394-5
pubmed: 27428269
Am J Public Health. 2012 Jul;102(7):1267-73
pubmed: 22594719
Public Health Rep. 1994 Jan-Feb;109(1):26-41
pubmed: 8303011
Cancer. 1998 Jan 1;82(1):219-25
pubmed: 9428500
Am J Epidemiol. 2011 Oct 1;174(7):769-78
pubmed: 21856649

Auteurs

Julia B Ward (JB)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill; Carolina Population Center, University of North Carolina, Chapel Hill; Social and Scientific Systems, Inc., Durham, NC.

Danielle R Gartner (DR)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill; Carolina Population Center, University of North Carolina, Chapel Hill.

Katherine M Keyes (KM)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; Center for Research on Society and Health, Universidad Mayor, Providencia, Santiago, Chile.

Mike D Fliss (MD)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill.

Elizabeth S McClure (ES)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill; Carolina Population Center, University of North Carolina, Chapel Hill.

Whitney R Robinson (WR)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill; Carolina Population Center, University of North Carolina, Chapel Hill; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill. Electronic address: whitney_robinson@unc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH